Compare · BGLC vs CNC
BGLC vs CNC
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.11B, about 6065.8x BGLC ($5.3M).
- Over the past year, BGLC is down 27.5% and CNC is up 16.7% - CNC leads by 44.3 points.
- CNC has been more active in the news (6 items in the past 4 weeks vs 2 for BGLC).
- CNC has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Centene Corporation
- Price
- $2.21+3.76%
- $65.03+4.36%
- Market cap
- $5.3M
- $32.11B
- 1M return
- -4.33%
- +18.39%
- 1Y return
- -27.54%
- +16.74%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 6
- Recent ratings
- 0
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest BGLC
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- SEC Form 10-K filed by BioNexus Gene Lab Corp
- SEC Form NT 10-K filed by BioNexus Gene Lab Corp
- BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest CNC
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Centene upgraded by Deutsche Bank with a new price target
- New insider Finke Daniel P claimed ownership of 228,127 shares (SEC Form 3)
- New insider Carson Michael A claimed ownership of 123,707 shares (SEC Form 3)
- Centene Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- Director Tanji Kenneth was granted 3,992 shares, increasing direct ownership by 50% to 11,909 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 3,992 shares, increasing direct ownership by 19% to 24,748 units (SEC Form 4)
- Director Ford Monte E was granted 3,992 shares, increasing direct ownership by 37% to 14,827 units (SEC Form 4)